LncRNA和其他表观遗传学在三阴性乳腺癌中的研究进展

Research Progress of LncRNA and Other Epigenetics in Triple-negative Breast Cancer

因缺乏激素受体(HR)及人表皮生长因子受体(HER-2),三阴性乳腺癌(TNBC)对内分泌治疗及分子靶向治疗缺乏特异性,成为乳腺癌(BC)预后最差的类型之一。TNBC的治疗主要有化疗、放疗及外科手术,但效果仍不满意,促使我们致力于探索新的分子标志物或新的治疗靶点。长链非编码RNA(LncRNA)在TNBC靶向治疗中具有生物标记作用,LncRNA及其相关的表观遗传修饰都可能为三阴性乳腺癌的治疗提供新的靶点。本文回顾有关LncRNA及其他表观遗传改变作为TNBC生物标记的现有研究进展及其作为TNBC治疗靶点的潜在用途。

For lacking of HR and HER-2,triple-negative breast cancer(TNBC)is one type of breast cancers with the worst prognosis.The current treatments are mainly chemotherapy,radiotherapy and surgery,but the results are still not satisfactory,which leads us to explore the new molecular markers or new therapeutic targets..LncRNA and its related epigenetic modifications may provide new targets for the treatment of TNBC.This paper reviews the existing studies on LncRNA and other epigenetic changes as TNBC biomarkers and their potential use as TNBC therapeutic targets.